SynthesisScientific reports2025
Antioxidant and anticancer properties of citrus-mediated nanoformulations revealed by meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to explore and analyse the potential antioxidant and anticancer potential of various citrus-mediated nanoformulations (CMNs), focusing on their effectiveness in scavenging free radicals and inducing cytotoxicity in cancer cells. This research employs a meta-analysis approach to assess data from multiple studies on CMNs. This study is the first meta-analysis to evaluate the antioxidant and anticancer properties of CMNs concurrently. This study offers a novel perspective by examining citrus species, plant parts utilised, nanoparticle types, particle sizes, and coating materials. The analysis employs the Population, Intervention, Comparison, and Outcome (PICO) framework and complies with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The analysis utilizes Hedges' effect size and includes validation through fail-safe N. The IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.